Estimation of the Burden of Chronic and Allergic Pulmonary Aspergillosis in India
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: It would be of considerable interest to clinicians if the burden of chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA) in India were known. Herein, we estimate the burden of CPA following pulmonary tuberculosis (PTB), and ABPA (and severe asthma with fungal sensitization [SAFS]) complicating asthma. METHODS: We used the population estimates for India from the 2011 census data. The burden of asthma was estimated using three different methods (Global Initiative against Asthma [GINA] report statement, World Health Survey [WHS] estimates, Indian study on the epidemiology of asthma and chronic bronchitis [INSEARCH]). Global and India-specific figures were used for calculating the prevalence of ABPA and SAFS. The World Health Organization estimates were used for calculating PTB rates while the frequency of CPA was assessed from a previously published scoping review. Sensitivity analysis was performed to determine the burden in various scenarios. RESULTS: The total Indian population in 2011 was 1.2 billion. The asthma prevalence in adults was estimated at about 27.6 (range, 17-30) million. The burden of ABPA ranged from 0.12-6.09 million with different assumptions (best estimate, 1.38 [range, 0.86-1.52] million). The prevalence of SAFS was approximated at about 0.52-1.21 million (best estimate, 0.96 [range, 0.6-1.06] million). The incident TB cases were about 2.1 million while the annual incidence of CPA varied 27,000-0.17 million cases, with different estimates. If the mortality of CPA is estimated as 15% annually, the 5-year prevalence of CPA was placed at 290,147 cases with 5-year prevalence rate being 24 per 100,000. CONCLUSION: There is a significant burden of ABPA, SAFS and CPA in India. Prospective community-based studies are required to accurately determine the prevalence of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High quality large ABPA prevalence studies have not been done in India, but the proportion of asthmatics with ABPA appears to be higher than any other country [136].”
From Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision (2017) · cites this paper as [136]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A total of ~1,136,092 adults are estimated to have asthma in Ukraine.”
From Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision (2017) · cites this paper as [136]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“former was a questionnaire-based study that has lower sensitivity compared to other methods used for the estimation of asthma prevalence.[19, 29] The prevalence of ABPA complicating asthma is believed to 2.”
ResultAgarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J. F., Guleria, R., Moss, R., Denning, D. W., & ABPA complicating asthma ISHAM working group (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12141 · Cited by 896 · cited 1×
“[1] Of the various pulmonary diseases, allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA) generally occur in the immunocompetent host while invasive pulmonary aspergillosis manifests in the immunocompromised host.[2] ABPA complicates the course of asthma of any severity,[3] while…”
BackgroundSelf-citationThe link between fungi and severe asthma: A summary of the evidence
Denning, D. W., O'Driscoll, B. R., Hogaboam, C. M., Bowyer, P., & Niven, R. M. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00074705 · Cited by 824
Self-citationDenning, D. W., Pleuvry, A., & Cole, D. C. (2013) · Medical Mycology · doi:10.3109/13693786.2012.738312 · Cited by 495 · cited 5×
“The basis for the statistical calculations has been previously published.[15, 16] We used the population estimates for India from the 2011 census data for calculating the total and the adult (§15 years) population.”
BackgroundMethodInfluentialSelf-citationUnderlying conditions in chronic pulmonary aspergillosis including simple aspergilloma
Smith, N. L., & Denning, D. W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00054810 · Cited by 449
Self-citationGlobal burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis
Denning, D., Pleuvry, A., & Cole, D. (2011) · Bulletin of the World Health Organization · doi:10.2471/blt.11.089441 · Cited by 420 · cited 5×
“To calculate the burden of CPA, the 12month mortality following CPA was assumed to be 15% (range, 10%–25%).[15] We then converted annual incident cases into five-year period prevalence using attrition rates of 10%, 15% or 25% to deduct deaths (and resection surgery) annually over the 5-year period.”
BackgroundMethodInfluentialSelf-citationAllergic Bronchopulmonary Aspergillosis
Agarwal, R. (2009) · Chest · doi:10.1378/chest.08-2586 · Cited by 407
Self-citationDenning, D. W., O'Driscoll, B. R., Powell, G., Chew, F., Atherton, G. T., Vyas, A., Miles, J., Morris, J., & Niven, R. M. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200805-737oc · Cited by 343
Self-citationJindal, S. K., Aggarwal, A. N., Gupta, D., Agarwal, R., Kumar, R., Kaur, T., Chaudhry, K., & Shah, B. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0005 · Cited by 270
Self-citationAllergic Bronchopulmonary Aspergillosis
Agarwal, R., Gupta, D., Aggarwal, A. N., Behera, D., & Jindal, S. K. (2006) · Chest · doi:10.1378/chest.130.2.442 · Cited by 234
Self-citationAgarwal, R., Gupta, D., Aggarwal, A. N., Saxena, A. K., Chakrabarti, A., & Jindal, S. K. (2007) · Chest · doi:10.1378/chest.07-0808 · Cited by 228
Self-citationAspergilloma and residual tuberculous cavities—the results of a resurvey
(1970) · Tubercle · doi:10.1016/0041-3879(70)90015-2 · Cited by 201
Agarwal, R., Aggarwal, A. N., Gupta, D., & Jindal, S. K. (2009) · PubMed · Cited by 191
Self-citationSevere asthma with fungal sensitization
Agarwal, R. (2011) · Current Allergy and Asthma Reports · doi:10.1007/s11882-011-0217-4 · Cited by 188 · cited 1×
“The prevalence of severe asthma is 10% of the total asthma burden while the prevalence of fungal sensitization is about 35% (range, 30– 40%).[6, 25] The prevalence of SAFS was calculated as: adult prevalent asthma cases 6 0.”
MethodSelf-citationGlobal burden of chronic pulmonary aspergillosis complicating sarcoidosis
Denning, D. W., Pleuvry, A., & Cole, D. C. (2013) · European Respiratory Journal · doi:10.1183/09031936.00226911 · Cited by 180
Self-citationAgarwal, R., Maskey, D., Aggarwal, A. N., Saikia, B., Garg, M., Gupta, D., & Chakrabarti, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061105 · Cited by 174
Self-citationAgarwal, R., Vishwanath, G., Aggarwal, A. N., Garg, M., Gupta, D., & Chakrabarti, A. (2013) · Mycoses · doi:10.1111/myc.12075 · Cited by 150
Self-citationMaurya, V., Gugnani, H. C. C., Sarma, P. U., Madan, T., & Shah, A. (2005) · CHEST Journal · doi:10.1016/s0012-3692(15)34474-3 · Cited by 140
Aspergillosis: From Diagnosis to Prevention
Pasqualotto, A. C. (2009) · Springer eBooks · doi:10.1007/978-90-481-2408-4 · Cited by 131
Agarwal, R., Khan, A., Gupta, D., Aggarwal, A. N., Saxena, A. K., & Chakrabarti, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015346 · Cited by 126
Self-citationAspergillus in persistent lung cavities after tuberculosis
(1968) · Tubercle · doi:10.1016/s0041-3879(68)80002-9 · Cited by 103
Agbetile, J., Bourne, M., Fairs, A., Hargadon, B., Desai, D., Broad, C., Morley, J. P., Bradding, P., Brightling, C. E., Green, R. H., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.09.050 · Cited by 89
Allergic Bronchopulmonary Aspergillosis and Related Allergic Syndromes
Hogan, C., & Denning, D. (2011) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0031-1295716 · Cited by 89
Self-citationAl-shair, K., Atherton, G. T., Harris, C., Ratcliffe, L., Newton, P. J., & Denning, D. W. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit411 · Cited by 82
Self-citationDavies, D. (1968) · Tubercle · Cited by 75
Maurya, V. (2005) · CHEST Journal · doi:10.1378/chest.127.4.1252 · Cited by 73
Chowgule, R., Shetye, V., PARMAR, J. R., BHOSALE, A. M., KHANDAGALE, M. R., PHALNITKAR, S. V., & Gupta, P. C. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.2.9708064 · Cited by 72
Allergic Bronchopulmonary Aspergillosis in Asthma: Epidemiological, Clinical and Therapeutic Issues
Agarwal, R., & Chakrabarti, A. (2013) · Future Microbiology · doi:10.2217/fmb.13.116 · Cited by 59
Self-citationAspergillus in persistent lung cavities after tuberculosis. A report from the Research Committee.
Ass., B. T. (1968) · Tubercle · Cited by 57
Khan, Z. U., Sandhu, R., Randhawa, H. S., Menon, M. P. S., & Dusaj, I. S. (1976) · PubMed · Cited by 48
Prevalence of Aspergillus sensitisation in pulmonary tuberculosis-related fibrocavitary disease
Dhooria, S., Kumar, P. V., Saikia, B., Aggarwal, A. N., Gupta, D. K. B., Behera, D., Chakrabarti, A., & Agarwal, R. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0838 · Cited by 42
Self-citationMYCOLOGICAL AND SEROLOGICAL STUDY OF PULMONARY ASPERGILLOSIS IN CENTRAL INDIA
Kurhade, A., Deshmukh, J., Fule, R. P., Chande, C. A., & Akulwar, S. L. (2002) · Indian Journal of Medical Microbiology · doi:10.1016/s0255-0857(21)03246-1 · Cited by 39
Agarwal, R. (2012) · Expert Review of Respiratory Medicine · doi:10.1586/ers.12.35 · Cited by 34
Self-citationClinical Manifestations and Natural History of Allergic Bronchopulmonary Aspergillosis
Agarwal, R., & Chakrabarti, A. (2009) · Springer eBooks · doi:10.1007/978-90-481-2408-4_42 · Cited by 32
Self-citationPrevalence of Aspergillosis in chronic lung diseases.
Shahid, M., Malik, A., & Bhargava, R. K. (2001) · PubMed · Cited by 29
Ghosh, T., Dey, A., Biswas, D., Chatterjee, S., Haldar, N., & Maiti, P. K. (2010) · PubMed · Cited by 19
Pulmonary tuberculosis: tomographic evaluation in the active and post-treatment phases
Bombarda, S., Figueiredo, C. M., Seiscento, M., & Filho, M. T. (2003) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802003000500004 · Cited by 13
Cited by
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
“5% of asthma India [136] 1,380,000 114 2.”
BackgroundInfluentialSelf-citationAgarwal, R., Sehgal, I. S., Muthu, V., Denning, D. W., Chakrabarti, A., Soundappan, K., Garg, M., Rudramurthy, S. M., Dhooria, S., Armstrong-James, D., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00061-2024 · Cited by 261
Self-citationDevelopments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis
Agarwal, R., Sehgal, I. S., Dhooria, S., & Aggarwal, A. N. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1249853 · Cited by 174
Self-citationAgarwal, R., Dhooria, S., Singh Sehgal, I., Aggarwal, A. N., Garg, M., Saikia, B., Behera, D., & Chakrabarti, A. (2018) · Chest · doi:10.1016/j.chest.2018.01.005 · Cited by 172
Self-citationThe burden of serious human fungal infections in Brazil
Giacomazzi, J., Baethgen, L., Carneiro, L. C., Millington, M. A., Denning, D. W., Colombo, A. L., Pasqualotto, A. C., & in association with the LIFE program (2016) · Mycoses · doi:10.1111/myc.12427 · Cited by 164
Self-citation
Metadata
- Authors
- Agarwal, R., Denning, D. W., & Chakrabarti, A.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Manchester Academic Health Science Centre (GB)
- Corresponding author
- Agarwal, Ritesh
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-12-05
- Volume
- 9
- Issue
- 12
- Pages
- e114745
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4257713
- OpenAlex
- W2045304212
- Cited by
- 121
- References
- 37
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 9 · 2023: 14 · 2022: 12 · 2021: 9 · 2020: 10 · 2019: 12 · 2018: 7 · 2017: 8 · 2016: 8 · 2015: 17
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Greater South Information System
- Funders
- Pfizer
- AstraZeneca
- Gilead Sciences
- European Commission
- Astellas Pharma
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Keywords
- chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, pulmonary tuberculosis, disease burden estimation, asthma prevalence, prevalence, incidence, mortality, India
- MeSH terms
- Aspergillosis, Allergic Bronchopulmonary, Asthma, Chronic Disease, Humans, India, Tuberculosis, Pulmonary, Pulmonary Aspergillosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
